Creative medical technology holdings announces irb approval for fda cleared phase 1/2 clinical trial of novel cell therapy for the treatment of type 1 diabetes

Company reaches next clinical trial milestone for treatment of type 1 diabetes with the first novel allogenic cellular therapy in the dorsal artery of the pancreas in the united states phoenix , feb. 8, 2023 /prnewswire/ -- creative medical technology holdings, inc. (nasdaq: celz), a biotechnology company working to revolutionize care through the development of potentially best-in-class regenerative therapeutics, today announced that it has received institutional review board (irb) approval to proceed with its clinical trial for the treatment of type 1 diabetes with its celz-201 cell therapy. the u.s. food and drug administration (fda) had previously cleared the company's investigational new drug (ind) application within 30 days from submission.
CELZ Ratings Summary
CELZ Quant Ranking